Two drugmakers withdrew two indications for their drug Imbruvica (ibrutinib) — the treatment for mantle cell lymphoma and marginal zone lymphoma — after a failure to meet endpoints in a phase 3 study.

Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma. The pharmaceutical companies developing Imbruvica ...